
    
      This phase 2, open-label, multi-center trial to evaluate the safety, immunogenicity and
      preliminary clinical efficacy of intradermally-delivered SNS-301 delivered using the 3M®
      hollow microstructured transdermal system (hMTS) device in patients with ASPH+ high risk
      myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial
      population consists of high risk ≥ Intermediate Risk-3 (IR-3) MDS and CMML-2.
    
  